Mihael Hristos Polymeropoulos

This profile gathers the share dealings of Mihael Hristos Polymeropoulos in Vanda Pharmaceuticals Inc., where the filings describe the role as chief executive. The record holds 222 filings, for trades running from 6 November 2006 to 2 March 2026.

Market trades split into 28 purchases (€792k) and 119 sales (€27.8M). Taken together, the sales exceed the purchases by €27.0M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 15 share grants and 58 option exercises. Since January 2026: no purchases and 1 sale on the market.

Half of the purchases are above €23k and half below. On 10 out of 14 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 4 March 2026: an open-market sale of €1.1M, in Vanda Pharmaceuticals Inc. The last insider purchase was made public on 8 August 2025, 442 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.